Brief: Allergy Therapeutics Says Protect Trial Meets Primary Safety Endpoint At Highest Dose

Allergy Therapeutics

09/12/2025 07:38

Dec 9 (Reuters) - Allergy Therapeutics PLC AGY.L:

ALLERGY THERAPEUTICS  - PRIMARY SAFETY ENDPOINT MET IN PROTECT TRIAL

ALLERGY THERAPEUTICS PLC - PROTECT TRIAL MEETS PRIMARY SAFETY ENDPOINT AT HIGHEST DOSE

ALLERGY THERAPEUTICS - PRELIMINARY SAFETY DATA IN TRIAL SHOW THAT 2000-FOLD INCREASE IN DOSE OF VLP PEANUT HAS BEEN SAFE & WELL TOLERATED

Source text: ID:nRSI7153Ka

Further company coverage: AGY.L

 ((Reuters.Briefs@thomsonreuters.com;))